What You Should Know:
- PsychoGenics Inc., a provider of AI-enabled phenotypic drug discovery and preclinical CRO services launches eCube®, a novel pharmaco-electroencephalography (“pharmacoEEG”) platform.
The platform supports phenotypic drug discovery, which unlike traditional target-based drug discovery, can identify novel treatments with multiple targets.
How eCube Works
eCube measures drug-induced changes to EEG spectra data and utilizes machine learning classifiers trained
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Exec Hires: Clinical Trials Marketplace SubjectWell Appoints New CEO
What You Should Know:
- SubjectWell, the largest engagement platform for matching patients with chronic health conditions to new care options, announced that clinical industry veteran Fred Martin has joined SubjectWell as CEO.
- Fred will joins SubjectWell during a time of growth following the company’s Series B funding in November 2022, with the goal of accelerating technical solutions and building investor relations.
Fred Martin Bio
Fred brings more than 25 years of experience in
Read More
Dot Compliance Launches First AI Based ChatGPT Powered eQMS for Life Sciences
What You Should Know:
Dot Compliance, a leading provider of eQMS compliance solutions for the life sciences sector, has introduced an industry-first, ready-to-use AI-Based electronic Quality Management System for life sciences, powered by an embedded generative and predictive artificial intelligence.The system deploys ChatGPT combined with proprietary algorithms to optimize quality processes, automate tasks and help professionals working in quality assurance to focus on what really matters
Read More
Can Technology Live Up to Its Promise for Clinical Trials?
By creating efficiencies with technology, CROs have an opportunity to build clinical trials of the future.
For many years, artificial intelligence (AI), machine learning (ML) and natural language processing (NLP) had a reputation in the biopharmaceutical industry as flashy buzzwords, with little concrete evidence to back up their promise. Over time, this lack of understanding has created drawn-out anticipation, leaving many skeptical about the true value of these tools.
As the
Read More
Inato Raises $20M to Make Clinical Trials More Inclusive
What You Should Know:
- Inato, a technology platform that connects pharma companies (trial sponsors) with community-based trial sites raises $20M in new funding (A2) led by Cathay Innovation with participation from existing investor Obvious Ventures and new investors La Maison and Top Harvest Capital. Inato works with many of the top 30 pharmaceutical companies worldwide to make clinical trials more inclusive.
- The new funding will fuel Inato’s continued product innovation, international
Read More
Exploring The Value of Metaverse Use Cases in Life Sciences
What once seemed like science fiction, interacting with people across the world has become the new normal. While we have become increasingly accustomed to video calls and instant communication in recent years, forays into virtual worlds and extended realities are still relatively novel.
In a post-Covid world, it seems strange to think that video conferences and calls were not the norm only three years ago. But the value created by virtual interactions during the last several years has
Read More
23andMe, Novartis Launches Pilot for Lipoprotein(a) Education
What You Should Know:
- In support of Lipoprotein(a) Awareness Day, 23andMe, a human genetics and biopharmaceutical company, today announced a collaboration with Novartis to increase awareness for Lipoprotein(a) (Lp(a)).
- High levels of Lp(a) are associated with increased risk of heart attack, stroke and other life threatening conditions. The level of Lp(a), which can be detected through a simple blood test, is almost entirely determined by genes and is unrelated to diet, exercise or
Read More
NVIDIA Unveils Generative AI Service to Advance Life Sciences R&D
What You Should Know:
- NVIDIA today announced an expanded set of generative AI cloud services for customizing AI foundation models to accelerate the creation of new proteins and therapeutics, as well as research in the fields of genomics, chemistry, biology and molecular dynamics.
- Part of NVIDIA AI Foundations, the new BioNeMo™ Cloud service offering — for both AI model training and inference — accelerates the most time-consuming and costly stages of drug discovery. It
Read More
Are Hospitals Ready for Alzheimer’s Treatment Approval?
The FDA’s recent accelerated approval of Leqembi was welcome news across the Alzheimer’s community. However, few health systems, medical practices, or providers are prepared for the extraordinary public interest in a treatment for Alzheimer’s disease – especially not one targeting mild cognitive impairment (MCI) and early dementia due to Alzheimer’s disease – that is likely headed their way soon. The unprecedented scale of the public health and marketing campaigns, the high prevalence of MCI in
Read More
Accelerating Clinical Trials Through AI-Enabled Precision Oncology
The American Cancer Society’s Cancer Statistics 2023 report highlighted a few major accomplishments within oncology, such as decreased cancer mortality rates and increased trial diversity. However, there is still much work to be done. Especially with the multiple types of new and ongoing challenges clinicians and staff members are facing - such as high turnover rates, decreased budgets and increased feelings of burnout - taking the necessary steps to enhance clinical trial procedures is crucial
Read More
